CTRI/2020/09/027952已完成3 期
A Prospective, Randomized, Open-label, Comparative, Multi-Centric, Phase III Clinical Study to Evaluate the Efficacy and Safety of Triamcinolone Acetonide 0.1% w/w and Lignocaine Hydrochloride 2.0% w/w Oromucosal Gel with Dologel-CT (Choline Salicylate 8.7% w/w, Lignocaine Hydrochloride 2.0% w/w, and Benzalkonium Chloride 0.01% w/w) in Treatment of Recurrent Aphthous Stomatitis - TALO3001/ TAILOR
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A patient must fulfil all the following criteria for inclusion in this study:
- •1. Males and females between ages 18 and 50 years (both inclusive).
- •2. Females of childbearing potential must have a negative pregnancy test, be non-lactating, and willing to use adequate and reliable contraception (defined as intrauterine device, contraceptive pill or depot gestagen) throughout the study
- •3. History of recurrence ulcers in oral cavity with at least two episodes of minor and/or major RAS last year with no signs of systemic disease
- •4. Presence of mucosal oral ulcers, each measuring 2 mm to 3 cm in size
- •5. Moderate to severe pain (>= 40 mm on 100 mm VAS) on the day of baseline visit
- •6. Patients willing to comply with the study procedures and requirements
- •7. Patients willing to sign and date written informed consent to participate in the study
排除标准
- •A patient will not be included in the study if they meet any of the exclusion criteria:
- •1. History of systemic diseases/illnesses causing oral ulceration like autoimmune conditions (systemic lupus erythematosus, Kawasaki disease), inflammatory conditions (Crohnâ??s disease, ulcerative colitis), gluten-sensitive enteropathy, dermatoses, drug eruptions, Behcetâ??s disease, Reiter syndrome, allergic conditions
- •2. Patients with herpetiform ulceration
- •3. Ulcers present at pharyngeal area
- •4. Patients with significant past history of cardiovascular disease (e.g. bradycardia or impaired cardiovascular function, ischemic heart disease, severe shock), impaired hepatic and renal function, sepsis, epilepsy; diabetes, uncontrolled hypertension, acid peptic disease, iron deficiency anemia, bleeding disorders, erosive gastritis, asthma, dehydration, neutropenia, folic acid or tuberculosis, association of ulcers with luteal phase of menstruation in female patients and other infections that may contraindicate treatment, as per Investigator discretion
- •5. Patients diagnosed with anxiety, mental or psychological disorders
- •6. Patients known to have hematinic deficiency or getting treatment for same
- •7. Patients undergoing dental treatment, with removable prosthetic rehabilitations or orthodontic appliances or having active periodontitis
- •8. Known history of hypersensitivity to local anesthetics of the amide type (e.g. Prilocaine, Mepivacaine) ester local anesthetics or corticosteroids or to other components in the formulation like methylparaben and/or propyl paraben or to their metabolite para aminobenzoic acid or choline salicylate
- •9. Patients on concomitant medications that may interact with study medication like anti-arrhythmic (e.g. Mexiletine, Amiodarone), antidepressants, sedative-hypnotics, psychotropic drugs
- •10. Participation in any other clinical study in past 30 days
- •11. Patients with other mucosal lesions with minor/major RAS and/or bacterial, yeast, viral or fungal infection at or near the proposed area of topical application
- •12. Ingestion of any chemotherapeutic drugs, immunomodulators or systemic corticosteroids in the recent 1 year
- •13. Patients whose ulcers clinically seem malignant in nature to the Investigator
- •14. Females who are pregnant/planning to become pregnant/not ready to use contraceptive measures or are lactating
- •15. Patients who are unsuitable for any other reason to participate in the study in the opinion of the Investigator
- •16. Patients who uses topical gel other than the study medication
研究者
相似试验
已完成
3 期
A clinical trial to study the Effect and Safety of the Ropivacaine Readyfusor 2mg/ml as a continuous surgical site infusion device with device available in market for the Treatment of Post-Surgical Pain in lower abdominal surgeries.CTRI/2019/09/021200Cipla Ltd155
尚未招募
不适用
Efficacy and safety of Levonadifloxacin versus Teicoplanin-Azithromycin combination in hospitalized patients with Community Acquired Bacterial Pneumonia (CABP)CTRI/2022/05/042613Dr Anand Nikalje
尚未招募
4 期
To assess the efficacy and safety of a probiotic product (Streptococcus salivarius K12) in children with recurrent upper respiratory tract infection.CTRI/2024/01/061611Dr Reddy’s Laboratories Ltd
尚未招募
不适用
EEfficacy and safety of Levonadifloxacin with Teicoplanin-Aztreonam combination in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI) including diabetic foot infectioCTRI/2022/06/043031Dr Anand Nikalje
已完成
3 期
Desvenlafaxine succinate ER tablet in the Management of Major Depressive DisorderCTRI/2009/091/000129Emcure Pharmaceuticals Limited Pune